Overview of current microRNA biomarker signatures as potential diagnostic tools for leukaemic conditions

Buhagiar, Alfred; Borg, Joseph; Ayers, Duncan

doi:10.1016/j.ncrna.2020.02.001

Cited by 19 publications

(17 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The downregulation of miR-34a and miR-125a upregulation was found to be associated with RS [ 85 ]. MiR-155 was reported as the most prevalent oncomiR in B-cell malignancies and revealed as a poor predictor for CLL, as well as an indicator to predict the therapy response [ 84 , 86 ]. MiR-29a and miR-29b overexpression leads to aggressive CLL, as well as miR-155 [ 87 ].…”

Section: Introductionmentioning

confidence: 99%

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

2020

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia with high heterogeneity in the western world. Thus, investigators identified a number of prognostic biomarkers and scoring systems to guide treatment decisions and validated them in the context of immunochemotherapy. A better understanding of prognostic biomarkers, including serum markers, flow cytometry outcomes, IGHV mutation status, microRNAs, chromosome aberrations and gene mutations, have contributed to prognosis in CLL. Del17p/ TP53 mutation, NOTCH1 mutation, CD49d, IGHV mutation status, complex karyotypes and microRNAs were reported to be of predictive values to guide clinical decisions. Based on the biomarkers above, classic prognostic models, such as the Rai and Binet staging systems, MDACC nomogram, GCLLSG model and CLL-IPI, were developed to improve risk stratification and tailor treatment intensity. Considering the presence of novel agents, many investigators validated the conventional prognostic biomarkers in the setting of novel agents and only TP53 mutation status/del 17p and CD49d expression were reported to be of prognostic value. Whether other prognostic indicators and models can be used in the context of novel agents, further studies are required.

show abstract

Section: Introductionmentioning

confidence: 99%

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

2020

View full text Add to dashboard Cite

show abstract

“…However, differentiation of MSCs into osteoblasts is the main pathway of osteoblastic formation and plays a crucial role in bone formation and functional maintenance (7). Numerous studies have shown that microRNAs, as endogenous post-transcriptional regulators, play a key biological role in regulating proliferation and differentiation of stem cells (8,9). In this paper, the role and mechanism of miRNAs in the osteogenic differentiation of MSCs were summarized, and the regulatory function of miRNAs in this process was recognized, so as to have a deeper understanding of bone metabolic diseases related to this process.…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs Regulation in Osteogenic Differentiation of Mesenchymal Stem Cells

Han

Fan

2021

Front. Dent. Med

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are a kind of pluripotent stem cell with the potential of self-renewal and multidirectional differentiation. They can be obtained from a variety of tissues and can differentiate into a variety of cell types under different induction conditions, including osteoblasts. Because of this osteogenic property, MSCs have attracted much attention in the treatment of bone metabolism-related diseases. MicroRNAs (miRNAs), as an epigenetic factor, are thought to play an important regulatory role in the process of osteogenic differentiation of MSCs. In recent years, increasingly evidence shows that miRNAs imbalance is involved in the regulation of osteoporosis and fracture. In this review, miRNAs involved in osteogenic differentiation and their mechanisms for regulating the expression of target genes are reviewed. In addition, we also discuss the potential clinical applications and possible directions of this field in the future.

show abstract

“…MicroRNAs (miRNAs) are noncoding RNA molecules with short lengths (about 18–22 nt), which play major roles in the posttranscriptional regulation of protein expression. MiRNAs have been found to be associated with a wide range of human diseases, like tumors and cancers, cardiovascular diseases, neurodegenerative diseases, leukemia, and so on 1 , 2 . Therefore, many studies suggest that miRNA expression profiles can be diagnostic and prognostic biomarkers for diseases.…”

Section: Introductionmentioning

confidence: 99%

Improve sample preparation process for miRNA isolation from the culture cells by using silica fiber membrane

Chen

2020

Sci Rep

View full text Add to dashboard Cite

In clinical applications of miRNAs, the purity and quality of the testing samples are very critical, especially the obtained tissue sample volume is limited. If the extracted miRNAs are contaminated or different in quality before analysis, it will increase the variance of the analysis result and make the medical information judgment incorrect and cannot be portable. Herein, we improved the commercially extraction kit by realizing the fundamental mechanism and hoped to serve finding optimal procedures for increasing the recovery of miRNAs extracted from cultured cells. In the adsorption process, the factors, like increasing the ethanol concentration or adding Ca2+, could influence the RNA adsorption were investigated. For the elution process, the effect caused by raising the elution temperature and raising the pH value of elution buffer was studied. Finally, the conditions for miRNA extraction are optimal modified by using a 65% (v/v) solution of ethanol in the adsorption process, and using TE buffer with the pH value of 8.0 and raising the temperature to 55 °C in the elution. According to the quantified results, the improved extraction kit can promote the recovery of endogenous miR-21 by about 6 times by using the optimal extraction conditions comparing with the miRNeasy Mini Kit.

show abstract

Overview of current microRNA biomarker signatures as potential diagnostic tools for leukaemic conditions

Cited by 19 publications

References 55 publications

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

MicroRNAs Regulation in Osteogenic Differentiation of Mesenchymal Stem Cells

Improve sample preparation process for miRNA isolation from the culture cells by using silica fiber membrane

Contact Info

Product

Resources

About